Loading interface...

Nexavar 200 Tablet

Manufactured byBAYER PHARMACEUTICALS PVT LTD
ContainsSorafenib
Description

Nexavar 200 Tablet is used to treat and prevent the growth of certain types of cancers of the liver, kidney, and thyroid. This medicine is not recommended for use in patients below 18 years of age.

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now

Side effects

Major & minor side effects for Nexavar 200 Tablet

  • Abdominal and stomach pain
  • Bleeding gums
  • Clay colored stools
  • Coughing up blood
  • Nausea and Vomiting
  • Loss of appetite
  • Difficulty in breathing
  • Hair loss
  • Fatigue
  • Headache
  • Dizziness
  • Dark urine
  • Hand-foot skin reactions

Uses of Nexavar 200 Tablet

What is it prescribed for?

  • Hepatocellular carcinoma
  • Advanced Renal Cell Carcinoma (RCC)
  • Thyroid cancer
Read More
Concerns

Commonly asked questions

  • Onset of action
    The peak effect of this medicine can be observed within 3 hours of administration of the dose.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition

Allergy

This medicine is not recommended for use in patients with a known allergy to sorafenib or any other inactive ingredients present along with it.

Squamous cell lung cancer

This medicine is not recommended for use with carboplatin and paclitaxel in patients with squamous cell lung cancer due to the increased risk of worsening of the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women. All the risks and benefits should be discussed with the doctor before using this medicine. Your doctor may advise you to discontinue the drug or to discontinue breastfeeding based on your clinical condition
General warnings

Dermatological toxicities

Hand-foot skin reaction and rash represent the most common adverse drug reactions with this medicine which generally appear during the first six weeks of treatment. Management of dermatological toxicities may include topical therapies for symptomatic relief, temporary treatment discontinuation and/or dose modification, or in severe or persistent cases, permanent discontinuation of the treatment.

Hypertension

This medicine should be used with caution due to the increased risk of hypertension. It is usually mild to moderate, occurred early in the course of treatment, which is usually managed with standard antihypertensive therapy. Blood pressure should be monitored regularly while receiving this medicine. In cases of severe or persistent hypertension, or hypertensive crisis despite institution of antihypertensive therapy, permanent discontinuation of Nexavar 200 Tablet should be considered.

Hypoglycemia

This medicine should be used with caution due to the increased risk of low blood glucose levels. In the case of symptomatic hypoglycemia, Nexavar 200 Tablet should be temporarily interrupted. Blood glucose levels in diabetic patients should be monitored regularly in order to assess if anti-diabetic medicinal product's dosage needs to be adjusted. An alternative treatment option should be considered in some cases based on the clinical condition.

Bleeding

Increased risk of bleeding may occur with this medicine. It is advised to discontinue this medicine in case of serious bleeding events. Thyroid cancer patients with tracheal, bronchial, and esophageal infiltration should be treated with local therapy prior to administering this medicine due to the potential bleeding risk.

Heart Diseases

This medicine should be used with caution in patients with cardiac diseases due to the increased risk of decreased blood flow to the heart or heart attack. It is advised to discontinue the therapy (temporary or permanent) in patients who develop these conditions.

Driving or Operating machinery

Use of this medicine may cause dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience dizziness during the treatment with this medicine.

Use in Children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for the next scheduled dose, then the missed dose can be skipped. Do not double your dose to make up for the missed dose. Contact your doctor for further instructions if you miss more than one scheduled dose of this medicine.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Escitalopram

Ziprasidone

Efavirenz

Mifepristone

Clozapine

Moxifloxacin

Disease interactions

Lung disease

This medicine should be used with caution in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation due to the increased risk of the lung toxicity. Appropriate dose adjustments and frequent clinical monitoring are advised in such cases. Replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
The absorption of this medicine is reduced in the presence of food. Take this medicine on an empty stomach 1 hour before or 2 hours after a meal unless otherwise directed by your doctor.
Lab interactions
Information not available.
Take Nexavar 200 Tablet exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended. Take this medicine at least 1 hour before or 2 hours after the meal. You may require frequent blood tests and liver function tests while taking this medicine. You may also require frequent followups with your doctor to check the progress of treatment. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken on an empty stomach

To be taken as instructed by doctor

May cause sleepiness

How it works
This medicine works by inhibiting the actions of certain proteins that cause the cancer cells to multiply. This helps in stopping the growth and spread of cancer.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Antineoplastics, Multikinase inhibitors, VEGF/VEGFR inhibitors

Schedule

Schedule H

[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 24 September 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b50667e4-5ebc-4968-a646-d605058dbef0

[Internet]. Medicines.org.uk. 2018 [cited 24 September 2018]. Available from:

https://www.medicines.org.uk/emc/product/226#

[Internet]. Ebs.tga.gov.au. 2018 [cited 24 September 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07403-3&d=201809241016933

[Internet]. Drugbank.ca. 2018 [cited 24 September 2018]. Available from:

https://www.drugbank.ca/drugs/DB00398
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 24 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.